Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes (T2DM) and mild hyperglycemia

被引：0
作者：
Scherbaum, W. A.
Schweizer, A.
Mari, A.
Nilsson, P. M.
Lalanne, G.
Jauffret, S.
Foley, J. E.
机构：
来源：
DIABETES | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A134 / A134
页数：1
相关论文
共 50 条
[21]   One-Year Vildagliptin, Compared to Placebo, Treatment Does Not Affect Markers of Bone Resorption and Calcium Homeostasis in Drug-Naive Patients with Type 2 Diabetes and Mild Hyperglycemia [J].
Diamant, Michaela ;
Poelma, Marieke ;
Goede, Diane L. ;
Van Golen, Larissa W. ;
Van Genugten, Renate E. ;
Eekhoff, E. Marelise ;
Schweizer, Anja ;
Heine, Robert J. ;
Foley, James E. ;
Nijpels, Giel ;
Bunck, Mathijs C. .
DIABETES, 2010, 59 :A192-A193
[22]   Efficacy and Tolerability of Saxagliptin (SAXA) in Patients With Type 2 Diabetes Mellitus (T2DM) and a History of Cardiovascular Disease (CVD) [J].
Minervini, Gianmaria ;
Cook, William ;
Allen, Elsie .
DIABETES, 2013, 62 :A306-A306
[23]   Efficacy and Tolerability of MK-0893, a Glucagon Receptor Antagonist (GRA), in Patients with Type 2 Diabetes (T2DM) [J].
Engel, Samuel S. ;
Xu, Lei ;
Andryuk, Paula J. ;
Davies, Michael J. ;
Amatruda, John ;
Kaufman, Keith ;
Goldstein, Barry J. .
DIABETES, 2011, 60 :A85-A85
[24]   Safety and Tolerability of Linagliptin and Metformin in Combination for Patients with Type 2 Diabetes Mellitus (T2DM) [J].
Ross, Stuart A. ;
Haak, Thomas ;
Patel, Sanjay ;
Thiemann, Sandra ;
Schumacher, Helmut ;
Meinicke, Thomas .
DIABETES, 2014, 63 :A277-A277
[25]   Pioglitazone (PIO) improves glycemic control in drug-therapy naive patients with type 2 diabetes (T2DM) [J].
Herz, M ;
Tan, M ;
Johns, D ;
Robertson, KE ;
Gonzalez, B ;
Reviriego, J ;
Grossman, L .
DIABETES, 2002, 51 :A481-A481
[26]   Pioglitazone (PIO) improves atherogenic dyslipidemia in drug-therapy naive patients with type 2 diabetes (T2DM) [J].
Tan, MH ;
Herz, M ;
Johns, D ;
Robertson, KE ;
Gonzalez, B ;
Reviriego, J ;
Grossman, LD .
DIABETES, 2002, 51 :A497-A497
[27]   Rosiglitazone/Metformin (RSG/MET) fixed dose combination (FDC) is effective and well-tolerated in drug-naive type 2 diabetes, mellitus (T2DM) subjects with severe hyperglycemia [J].
Rosenstock, J ;
Strow, L ;
Rood, J ;
Huang, C ;
Biswas, N ;
Cobitz, AR ;
Davies, MJ .
DIABETES, 2005, 54 :A127-A127
[28]   Empagliflozin monotherapy in drug-naive patients with Type 2 diabetes [J].
Roden, M. ;
Weng, J. ;
Merker, L. ;
Christiansen, A. Vedel ;
Roux, F. ;
Salsali, A. ;
Kim, G. ;
Stella, P. ;
Woerle, H. J. ;
Broedl, U. C. .
DIABETIC MEDICINE, 2015, 32 :89-89
[29]   A single dose of vildagliptin (VILDA) decelerates gastric emptying (GE) in patients with type 2 diabetes (T2DM) [J].
Woerle, Hans J. ;
Lindenberger, Thilo ;
Lfnke, Rainer ;
Foley, James E. ;
Ligueros-Saylan, Monica A. ;
Zhang, Yiming ;
He, Yan-Ling ;
Beglinger, Christoph ;
Goeke, Burkhard ;
Schirra, Joerg .
DIABETES, 2007, 56 :A133-A133
[30]   Benefits of combination with rosiglitazone (RSG) and metformin (MET) over uptitration to maximal dose MET in previously drug-naive type 2 diabetes mellitus (T2DM) patients [J].
Garber, A ;
Wooddell, MJ ;
Strow, LJ ;
Waterhouse, BR ;
Cobitz, AR .
DIABETES, 2004, 53 :A475-A475
12345